Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-daily GLP-1 receptor agonist FDA-approved for type 2 diabetes. Shorter-acting than semaglutide, with a stronger effect on postprandial glucose. Also available in a fixed-ratio combination with insulin glargine (Soliqua).
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and tirzepatide. While largely superseded by newer agents for weight loss, it remains FDA-approved and widely prescribed, particularly for patients who tolerate it well or have established insurance coverage.
Activates GLP-1 receptors, stimulating glucose-dependent insulin secretion and suppressing glucagon. Its shorter duration of action produces a more pronounced effect on gastric emptying and postprandial glucose compared to longer-acting GLP-1 agonists.
Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Requires daily injection due to a shorter half-life than semaglutide. The daily dosing schedule is both a limitation and, for some patients, a feature — easier to stop quickly if side effects occur.
- Type 2 diabetes (adjunct to diet and exercise)
- Postprandial glucose control
- Combined with basal insulin (Soliqua)
- Weight management (FDA-approved as Saxenda)
- Type 2 diabetes (FDA-approved as Victoza)
- Cardiovascular risk reduction
- Nausea and vomiting (common, usually transient)
- Diarrhea
- Headache
- Hypoglycemia when combined with sulfonylureas
- Pancreatitis (rare)
- Nausea and vomiting (common, especially during titration)
- Pancreatitis risk
- Gallbladder disease
- Potential thyroid C-cell tumor risk (animal data)
- Daily injection burden vs. weekly alternatives
FDA-approved as Adlyxin (2016) for type 2 diabetes. Also available as Soliqua 100/33 (fixed-ratio combination with insulin glargine). Less weight loss than semaglutide but better postprandial control.
FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). The LEADER trial demonstrated cardiovascular risk reduction in diabetic patients. Largely superseded by semaglutide and tirzepatide for new prescriptions due to superior efficacy and weekly dosing, but remains a valid option with established long-term safety data.
- Lixisenatide in type 2 diabetes (GetGoal trials)
2013 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.